BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-2001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-2001\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05862012-3278@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:ABBV-2001: Phase 1 readout est. (NCT05862012)
DESCRIPTION:ABBV-2001\, phase 1\, Multiple Myeloma.\nStudy: Study of ISB 20
 01 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)\nEstimated primary
  completion: July 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/abbv-2001#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05862012
URL:https://assetmemo.bio/drug/abbv-2001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3278@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:ABBV-2001: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:ABBV-2001\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Change in Disease Activity and Adverse Events (AE)s in Adult Particip
 ants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antib
 odies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nEst
 imated primary completion: December 2035. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abbv-2001#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/abbv-2001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
